Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Qiagen, BioHelix in helicase-dependent isothermal DNA amplification agreement
June 2008
SHARING OPTIONS:

VENLO, The Netherlands—Qiagen and privately held BioHelix Corp. announced they entered into a non-exclusive worldwide license and supply agreement for BioHelix's proprietary Helicase Dependent Amplification technology (HDA). HDA is a versatile assay technology to detect and analyze biological target molecules such as DNA and RNA by amplifying target specific genetic information with the highest level of sensitivity and specificity. Financial terms were not disclosed. This agreement adds a further amplification technology to Qiagen's intellectual property estate of amplification and assay technologies that includes numerous PCR and PCR-similar technologies as well as technologies such as rolling circle amplification (RCA) and whole genome/transcriptome amplification.







 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.